Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Celyad Oncology (OTCPK:CLYYF) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Celyad Oncology's net income from continuing operations for the
six
months ended in Dec. 2025 was $5.28 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Celyad Oncology's depreciation, depletion and amortization for the
six
months ended in Dec. 2025 was $-0.04 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Celyad Oncology's change in working capital for the
six
months ended in Dec. 2025 was $-1.74 Mil. It means Celyad Oncology's working capital
declined by $1.74 Mil
from Jun. 2025 to Dec. 2025 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Celyad Oncology's cash flow from deferred tax for the
six
months ended in Dec. 2025 was $0.00 Mil.
Celyad Oncology's cash from discontinued operating Activities for the
six
months ended in Dec. 2025 was $0.00 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Celyad Oncology's asset impairment charge for the
six
months ended in Dec. 2025 was $0.00 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Celyad Oncology's stock based compensation for the
six
months ended in Dec. 2025 was $0.07 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Celyad Oncology's cash flow from others for the
six
months ended in Dec. 2025 was $-7.81 Mil.
Celyad Oncology Cash Flow from Operations Related Terms
Celyad Oncology Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Celyad Oncology's Cash Flow from Operations for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of $-8.02 Mil mean?
Celyad Oncology (CLYYF) has a Cash Flow from Operations of $-8.02 Mil as of Dec. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Celyad Oncology and its competitors.
Is Celyad Oncology's Cash Flow from Operations too high?
Celyad Oncology's current Cash Flow from Operations is $-8.02 Mil. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Cash Flow from Operations compare to VRTX and REGN?
Celyad Oncology's Cash Flow from Operations of $-8.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Celyad Oncology and its competitors. Celyad Oncology's current Cash Flow from Operations is $-8.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.20 — trading 33.3% above its estimated fair value. The current Cash Flow from Operations is $-8.02 Mil. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Cash Flow from Operations is $-8.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.20 is trading 33.3% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
Cash Flow from Operations: $-8.02 Mil
GF Value™: $0.15 vs. price of $0.20 (33.3% above fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
